AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for PR domain zinc finger protein 8

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9NQV8

UPID:

PRDM8_HUMAN

Alternative names:

PR domain-containing protein 8

Alternative UPACC:

Q9NQV8; A8K7X2; Q6IQ36

Background:

PR domain zinc finger protein 8, alternatively known as PR domain-containing protein 8, plays a crucial role in various biological processes. It acts as a probable histone methyltransferase, targeting 'Lys-9' of histone H3, and is involved in transcriptional repression of steroidogenesis marker genes such as CYP17A1 and LHCGR. Additionally, it forms a complex with BHLHE22 to control genes essential for neural development and neuronal differentiation. In the retina, it is vital for the survival of rod bipolar and type 2 OFF-cone bipolar cells.

Therapeutic significance:

The protein's association with Epilepsy, progressive myoclonic 10, a disorder characterized by a spectrum of symptoms including myoclonus, ataxia, and cognitive decline, underscores its therapeutic significance. Understanding the role of PR domain zinc finger protein 8 could open doors to potential therapeutic strategies for this and related neurological conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.